Li-Wen Huang1, Sandy W Wong2, Charalambos Andreadis3, Rebecca L Olin3. 1. Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, 505 Parnassus Ave, Hematology/Oncology Office, M1286, San Francisco, CA, 94143, USA. li-wen.huang@ucsf.edu. 2. Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, 400 Parnassus Ave, Box 1270, San Francisco, CA, 94143, USA. 3. Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, 400 Parnassus Ave, Box 0324, San Francisco, CA, 94143, USA.
Abstract
PURPOSE OF REVIEW: Hematologic malignancies are common and difficult to treat in older adults. In this review, we focus on recent updates in diseases with several novel agents relevant to older adults-acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). RECENT FINDINGS: In AML, CPX-351 offers a new induction chemotherapy for secondary AML that prolongs survival, and venetoclax and IDH inhibitors are efficacious and well tolerated. In CLL, chemoimmunotherapy is being replaced by monoclonal antibodies and small molecule inhibitors that are more effective and better tolerated. In MM, new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies have expanded treatment options for older patients. The introduction of novel agents has dramatically shifted the landscape of therapeutic options for older adults with hematologic malignancies. Clinical trials in older adults are needed to expand treatment options for these patients.
PURPOSE OF REVIEW: Hematologic malignancies are common and difficult to treat in older adults. In this review, we focus on recent updates in diseases with several novel agents relevant to older adults-acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). RECENT FINDINGS: In AML, CPX-351 offers a new induction chemotherapy for secondary AML that prolongs survival, and venetoclax and IDH inhibitors are efficacious and well tolerated. In CLL, chemoimmunotherapy is being replaced by monoclonal antibodies and small molecule inhibitors that are more effective and better tolerated. In MM, new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies have expanded treatment options for older patients. The introduction of novel agents has dramatically shifted the landscape of therapeutic options for older adults with hematologic malignancies. Clinical trials in older adults are needed to expand treatment options for these patients.
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson Journal: N Engl J Med Date: 2008-08-28 Impact factor: 91.245
Authors: María-Victoria Mateos; José M Hernández; Miguel T Hernández; Norma C Gutiérrez; Luis Palomera; Marta Fuertes; Pedro Garcia-Sanchez; Juán J Lahuerta; Javier de la Rubia; María-José Terol; Ana Sureda; Joan Bargay; Paz Ribas; Adrian Alegre; Felipe de Arriba; Albert Oriol; Dolores Carrera; José García-Laraña; Ramón García-Sanz; Joan Bladé; Felipe Prósper; Gemma Mateo; Dixie-Lee Esseltine; Helgi van de Velde; Jesús F San Miguel Journal: Haematologica Date: 2008-03-05 Impact factor: 9.941
Authors: Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund Journal: Blood Date: 2008-11-13 Impact factor: 22.113